COMPARISON OF USE OF LOW DOSE VAGINAL MISOPROSTOL FOR SECOND AND EARLY THIRD TRIMESTER PREGNANCY TERMINATION IN WOMEN WITH PRIOR CAESAREAN AND UNSCARRED UTERI
Öz
Objective: The study was aimed to determine the safety and efficacy of the vaginal administration of low dose misoprostol for late pregnancy termination in women with prior caesarean and unscarred uteri.
Study design: A retrospective study was carried out from January 2008 to June 2012 on 209 pregnant women who underwent termination of pregnancy in the second and early third trimester. Among the women, 173 did not have a uterine scar (Group 1) while 36 had a history of prior caesarean (Group 2). The induction-to-abortion interval, the rate of complications and failureand the need for a different method during the process were assessed.
Results: In group 1, 145 of patients (83.8%) delivered vaginally in 48 hours, the mean duration of the induction-to-abortion interval was 21±10.3 hours. In this group, 11 patients (6.3%) needed one or more different methods and one case of uterine rupture (0.57%) was observed. In group 2, 26 of patients (72.2%) delivered vaginally in 48 hours (p=0.11), the mean induction-abortion interval was 22.7±10.8 hours (p=0.45). Six patients (16.7%) needed a different method (p=0.05) and there was also one case (2.7%) of ruptured uterus (p=0.28).
Conclusion: Administration of low-dose vaginal misoprostol appears to be effective without excessive side effects or complications for late pregnancy termination.
Key words: Misoprostol, pregnancy termination, uterine rupture,
Anahtar Kelimeler
Kaynakça
- New US food and drug administration labeling on Cytotec (misoprostol) use and pregnancy. ACOG Committee Opinion 283. Washington, DC: American College of Obstetricians and Gynecologists 2003. Int J Gynaecol Obstet. 2003;82:137-8
- WHO. Safe abortion: technical and policy guidance for health system. Geneva: WHO; 2003.
- Ho PC, Blumenthal PD, Gemzell-Danielsson K, Gomez Ponce de LR, Mittal S, Tang OS. Misoprostol for the termination of pregnancy with a live fetus at 13 to 26 weeks. Int J Gynaecol Obstet 2007;99(2):178–81.
- Lehair J, Lemarie P, Helleringer M, Manini P. Expulsion of arrested pregnancy product in the second trimester using a prostaglandin E1 analog administered intravaginally. Apropos of 12 cases. Rev Fr Gynecol Obstect 1989;84:19-23.
- Bugalho A, Bique C, Almeida L, Fau´ndes A. The effectiveness of intravaginal misoprostol (Cytotec) in inducing abortion after eleven weeks of pregnancy. Stud Fam Plann 1993;24:319-23.
- Elsheikh A, Antsaklis A, Mesogitis S, Papantoniou N, Rodolakis A, Vogas E, Michalas S. Use of misoprostol for the termination of second trimester pregnancies. Arch Gynecol Obstet 2001;265:204-6.
- Nigam A, Singh VK, Prakash A. Vaginal vs. oral misoprostol for mid-trimester abortion. Int J Gynaecol Obstet 2006;92:270–1.
- Dickinson JE, Evans SF. A comparison of oral misoprostol with vaginal misoprostol administration in second-trimester pregnancy termination for fetal abnormality. Obstet Gynecol 2003;101:1294–9.
Ayrıntılar
Birincil Dil
İngilizce
Konular
Sağlık Kurumları Yönetimi
Bölüm
-
Yazarlar
Özlem Dural
Bu kişi benim
Gökhan Yıldırım
Bu kişi benim
Melih Bestel
Bu kişi benim
Sedat Tekeli
Bu kişi benim
Halil Aslan
Bu kişi benim
Yayımlanma Tarihi
2 Ağustos 2016
Gönderilme Tarihi
24 Ocak 2016
Kabul Tarihi
-
Yayımlandığı Sayı
Yıl 2016 Cilt: 79 Sayı: 2